Recombinant Human Glucosylceramidase/GBA Protein, CF
Recombinant Human Glucosylceramidase/GBA Protein, CF Summary
Product Specifications
Ala40-Gln536, with a C-terminal 6-His tag
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
7410-GHB
Formulation | Supplied as a 0.2 μm filtered solution in Sodium Citrate. |
Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Assay Procedure
- Assay Buffer: 50 mM Sodium Citrate, 25 mM Sodium Cholate, 5 mM DTT, pH 6.0
- Stop solution: 0.5 M Glycine, 0.3 M NaOH (~pH 10)
- Recombinant Human Glucosylceramidase/GBA (rhGBA) (Catalog # 7410-GHB)
- Substrate: 4-Methylumbelliferyl-beta -D-glucopyranoside (Sigma, Catalog # M3633), 10 mM stock in DMSO
- F16 Black Maxisorp Plate (Nunc, Catalog # 475515)
- Fluorescent Plate Reader (Model: SpectraMax Gemini EM by Molecular Devices) or equivalent
- Dilute rhGBA to 0.2 ng/µL in Assay Buffer.
- Dilute Substrate to 6 mM in Assay Buffer.
- Load 25 µL of 0 2 ng/µL rhGBA into wells of a plate, and start the reactions by adding 25 μL of 6 mM Substrate. Include a Substrate Blank containing 25 µL of Assay Buffer and 25 µL of 6 mM Substrate.
- Seal plate and incubate at 37 °C for 20 minutes.
- After incubation, stop the reactions by adding 50 µL of Stop Solution to each well.
- Read at excitation and emission wavelengths of 365 nm and 445 nm (top read), respectively, in endpoint mode.
- Calculate specific activity:
Specific Activity (pmol/min/µg) = | Adjusted Fluorescence* (RFU) x Conversion Factor** (pmol/RFU) |
Incubation time (min) x amount of enzyme (µg) |
*Adjusted for Substrate Blank
** Derived using calibration standard 4methylumbelliferone (Sigma, Catalog # 69580).
- rhGBA: 0.005 µg
- Substrate: 1.5 mM
Scientific Data
Recombinant Human Glucosylceramidase/GBA Protein, CF (Catalog # 7410-GHB) cleaves the beta-glucosidic linkage of glucosylceramide, an intermediate in glycolipid metabolism.
Recombinant Human Glucosylceramidase/GBA Protein, CF (Catalog # 7410-GHB) is measured by its ability to hydrolyze 4-methylumbelliferyl-beta -D-glucopyranoside.
2 μg/lane of Recombinant Human Glucosylceramidase/GBA Protein (Catalog # 7410-GHB) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 60-75 kDa.
Reconstitution Calculator
Background: Glucosylceramidase/GBA
Glucosylceramidase is a lysosomal enzyme that cleaves the beta-glucosidic linkage of glucosylceramide (1, 2), an intermediate in glycolipid metabolism. The mature enzyme has 497 amino acids with a molecular weight of 62 kDa (3). Glycosylation occurs at four of five N-glycosylation sites and is essential for the trafficking and activity of the enzyme (4). The enzyme is activated in lysosomes by saposin C, although the mechanism of activation is not well understood (5). Defects in Glucosylceramidase are the cause of Gaucher disease, also known as glucocerebrosidase deficiency (6). Gaucher disease is the most prevalent lysosomal storage disease, characterized by accumulation of glucosylceramide in the reticulo-endothelial system. Symptoms of Gaucher disease may include enlarged spleen and liver, liver malfunction, skeletal disorders and bone lesions, severe neurologic complications, swelling of lymph nodes, anemia, low blood platelets and yellow fatty deposits on the white of the eye (7). Currently, enzyme replacement therapy is used to treat patients with the disease (8, 9).
- Sorge, J. et al. (1985) Proc. Natl. Acad. Sci. USA 82:7289.
- Ginns, E. I. et al. (1984) Biochem. Biophyl. Res. Commun. 123:574.
- Horowitz, M. et al. (1989) Genomics 4:87.
- Grace, M.E. et al. (1994) J. Biol. Chem. 269:2283.
- Bruhn, h. (2005) Biochem. J. 389:249.
- Liou, B. et al. (2006) J. Biol. Chem. 281:4242.
- Grabowski, G.A. (2008). Lancet 372:1263.
- Zheng, W. et al. (2007) Proc. Natl. Acad. Sci. USA 104:13192.
- Beutler, E. and Gelbart, T. (1996) Hum. Mutat. 8:207.
Citations for Recombinant Human Glucosylceramidase/GBA Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
11
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
Reduced progranulin increases tau and ?-synuclein inclusions and alters mouse tauopathy phenotypes via glucocerebrosidase
Authors: Takahashi, H;Bhagwagar, S;Nies, SH;Ye, H;Han, X;Chiasseu, MT;Wang, G;Mackenzie, IR;Strittmatter, SM;
Nature communications
Species: Mouse
Sample Types: Whole Cells
Applications: Bioassay -
The SATB1-MIR22-GBA axis mediates glucocerebroside accumulation inducing a cellular senescence-like phenotype in dopaminergic neurons
Authors: Russo, T;Kolisnyk, B;Bs, A;Kim, TW;Martin, J;Plessis-Belair, J;Ni, J;Pearson, JA;Park, EJ;Sher, RB;Studer, L;Riessland, M;
bioRxiv : the preprint server for biology
Species: Human
Sample Types: Whole Cells, Transfected Whole Cells
Applications: Bioassay -
Recapture Lysosomal Enzyme Deficiency via Targeted Gene Disruption in the Human Near-Haploid Cell Line HAP1
Authors: A Brown, J Zhang, B Lawler, B Lu
Genes, 2021-07-15;12(7):.
Species: Human
Sample Types:
Applications: Cell Culture -
Substrate reduction therapy for Krabbe disease and metachromatic leukodystrophy using a novel ceramide galactosyltransferase inhibitor
Authors: MC Babcock, CR Mikulka, B Wang, S Chandriani, S Chandra, Y Xu, K Webster, Y Feng, HR Nelvagal, A Giaramita, BK Yip, M Lo, X Jiang, Q Chao, JC Woloszynek, Y Shen, S Bhagwat, MS Sands, BE Crawford
Scientific Reports, 2021-07-14;11(1):14486.
Species: Human
Sample Types: Recombinant Protein
Applications: Bioassay -
Validation and assessment of preanalytical factors of a fluorometric in vitro assay for glucocerebrosidase activity in human cerebrospinal fluid
Authors: L Oftedal, J Maple-Grød, MGG Førland, G Alves, J Lange
Scientific Reports, 2020-12-16;10(1):22098.
Species: Human
Sample Types: CSF
Applications: Cell Culture -
Targeted delivery of lysosomal enzymes to the endocytic compartment in human cells using engineered extracellular vesicles
Authors: MA Do, D Levy, A Brown, G Marriott, B Lu
Sci Rep, 2019-11-21;9(1):17274.
Species: N/A
Sample Types: Protein
Applications: Enzyme Assay -
Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations
Authors: H Li, A Ham, TC Ma, SH Kuo, E Kanter, D Kim, HS Ko, Y Quan, SP Sardi, A Li, O Arancio, UJ Kang, D Sulzer, G Tang
Autophagy, 2018-10-12;15(1):113-130.
Species: Mouse
Sample Types: Tissue Homogenates
-
?-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism
Authors: SP Yun, D Kim, S Kim, S Kim, SS Karuppagou, SH Kwon, S Lee, TI Kam, S Lee, S Ham, JH Park, VL Dawson, TM Dawson, Y Lee, HS Ko
Mol Neurodegener, 2018-01-08;13(1):1.
Species: Mouse
Sample Types: Whole Cells
Applications: Bioassay -
Fluorescence-Quenched Substrates for Quantitative Live Cell Imaging of Glucocerebrosidase Activity
Authors: RA Ashmus, DL Shen, DJ Vocadlo
Meth. Enzymol., 2017-10-31;598(0):199-215.
Species: Human
Sample Types:
Applications: Bioassay -
Lysosomal Enzyme Glucocerebrosidase Protects against Abeta1-42 Oligomer-Induced Neurotoxicity.
Authors: Choi S, Kim D, Kam T, Yun S, Kim S, Park H, Hwang H, Pletnikova O, Troncoso J, Dawson V, Dawson T, Ko H
PLoS ONE, 2015-12-02;10(12):e0143854.
Species: Human
Sample Types: Tissue Homogenates
Applications: Bioassay -
Tool compounds robustly increase turnover of an artificial substrate by glucocerebrosidase in human brain lysates.
Authors: Berger, Zdenek, Perkins, Sarah, Ambroise, Claude, Oborski, Christin, Calabrese, Matthew, Noell, Stephen, Riddell, David, Hirst, Warren D
PLoS ONE, 2015-03-12;10(3):e0119141.
Species: Human, Mouse
Sample Types: Tissue Homogenates
Applications: Enzyme Assay
FAQs
-
Why is DTT (dithiothreitol) added to the assay buffer in the assay described for Recombinant Human Glucosylceramidase/GBA Protein, CF, Catalog # 7410-GHB?
The 5 mM DTT is added to the assay buffer in the assay protocol for catalog # 7410-GHB to prevent interchain disulfide bond formation that can cause aggregation of the protein and loss of enzyme activity over time.
Reviews for Recombinant Human Glucosylceramidase/GBA Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human Glucosylceramidase/GBA Protein, CF and earn rewards!
Have you used Recombinant Human Glucosylceramidase/GBA Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image